Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Resistant Pseudomos aeruginosa Infections - Overview
Resistant Pseudomos aeruginosa Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Resistant Pseudomos aeruginosa Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Resistant Pseudomos aeruginosa Infections - Companies Involved in Therapeutics Development
Armata Pharmaceuticals
Biolytics Pharma
BiomX Inc
Boston Pharmaceuticals Inc
Lineus Bioscience Inc
Shionogi & Co Ltd
VetoRx Pharmaceuticals Inc
Resistant Pseudomos aeruginosa Infections - Drug Profiles
(cefepime + taniborbactam hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(ciprofloxacin + colistimethate sodium) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APPA-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic for Multi-Drug Resistant Pseudomos aeruginosa Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic for Pseudomos Aeruginosa Infection - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic for Resistant Pseudomos aeruginosa Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BOS-181 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BX-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cefiderocol sulfate tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PEG-2S - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Pseudomos aeruginosa Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Resistant Pseudomos aeruginosa Infections - Dormant Projects
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Resistant Pseudomonas aeruginosa Infections, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development for Resistant Pseudomonas aeruginosa Infections, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Resistant Pseudomonas aeruginosa Infections - Pipeline by Armata Pharmaceuticals, 2021
Resistant Pseudomonas aeruginosa Infections - Pipeline by Biolytics Pharma, 2021
Resistant Pseudomonas aeruginosa Infections - Pipeline by BiomX Inc, 2021
Resistant Pseudomonas aeruginosa Infections - Pipeline by Boston Pharmaceuticals Inc, 2021
Resistant Pseudomonas aeruginosa Infections - Pipeline by Linnaeus Bioscience Inc, 2021
Resistant Pseudomonas aeruginosa Infections - Pipeline by Shionogi & Co Ltd, 2021
Resistant Pseudomonas aeruginosa Infections - Pipeline by VenatoRx Pharmaceuticals Inc, 2021
Resistant Pseudomonas aeruginosa Infections - Dormant Projects, 2021
Resistant Pseudomonas aeruginosa Infections - Dormant Projects, 2021 (Contd..1)